

Colorado HB 19-1131 Disclosure

Gocovri® (Amantadine)

Supernus Pharmaceuticals, Inc. (Supernus) provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects Supernus Wholesale Acquisition Costs (“WAC”) for the Supernus Pharmaceuticals, Inc. product: Gocovri®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Gocovri®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Gocovri® (Amantadine)	17772-0085-60	Oral Capsule Extended Release 24 Hour 68.5 MG	\$3,432.11
Gocovri® (Amantadine)	17772-0170-60	Oral Capsule Extended Release 24 Hour 137 MG	\$3,432.11

Generic versions of Gocovri are not currently available.

For more information on the price disclosure requirements, please contact the Colorado State Board of Pharmacy at:

State Board of Pharmacy
1560 Broadway, Suite 1350
Denver, CO 80202
Ph. (303) 894-7800 | Fax: (303) 894-7692 | Email: dora_pharmacyboard@state.co.us